CPAY — Corpay, Inc.

Sentiment is genuinely bullish and the tape supports it. The Aug 5, 2026 Q2 print delivered ~$1.34B revenue (+21% YoY) and $7.00 adjusted cash EPS (+36% YoY), and management raised FY2026 guidance to $5.29–5.33B revenue and $27.15–$27.55 adjusted EPS. Sell-side followed hard: Wolfe Research lifted its target to $530 on Aug 24, 2026, and Scotiabank initiated at Buy with a Street-high $536 on Aug 31, 2026. The rating mix is 14 Buy / 4 Hold / 0 Sell, with a consensus target of $456.50 (recent average $462.18) versus the $408.22 close on 2026-09-13 — roughly 12% implied upside. Momentum as of 2026-09-13: +28.56% over six months, +14.63% over three months, but -0.36% over one month and -1.96% over the past week, i.e. post-earnings enthusiasm has cooled into a sideways consolidation rather than a fresh leg up.

Revenue growth is clearly accelerating, not decelerating. Quarterly revenue ran $1.029B (Q3 2024) → $1.034B (Q4 2024) → $1.006B (Q1 2025) → $1.102B (Q2 2025) → $1.172B (Q3 2025) → $1.248B (Q4 2025) → $1.261B (Q1 2026) → $1.339B (Q2 2026). YoY growth went roughly +6% in Q3 2024 → +7.5% in Q1 2025 → +13–14% through mid/late 2025 → +25.4% in Q1 2026 and +21.5% in Q2 2026. That is a real inflection, helped by the rotation toward digital B2B payables and cross-border. Profitability tells the opposite story: operating margin was 43.5% in Q2 2025 but only 35.2% in Q2 2026, even though gross margin improved to 79.4% from 78.4% — operating expense dollars jumped ~54% YoY ($592M vs $384M) against 21.5% revenue growth. GAAP diluted EPS fell to $3.70 from $3.98, and Q2 2026 net income of $248M was well below Q1 2026's $350M despite higher revenue. H1 2026 net margin of 23.0% sits ~200bp below H1 2025's 25.0% on 23.3% revenue growth. Net read: the revenue inflection looks structural, the margin/FCF translation looks strained. Also note management's own FY2026 revenue guide of $5.29–5.33B implies H2 2026 revenue of $2.69–2.73B, i.e. only ~11–13% YoY growth versus the 21–25% just delivered — either conservatism or a genuine second-half slowdown baked into guidance.

As of 2026-09-13, CPAY is expensive on trailing GAAP earnings and reasonable on forward cash earnings. TTM P/E is 24.5x against a 5-year average of 20.17x, and P/S of 5.315x is essentially on top of its 5-year average of 5.33x — which is why the deterministic screener calls valuation 'Neutral vs. its own history.' But on the FY2026 adjusted cash EPS the company just guided to ($27.15–$27.55; consensus $27.385), the forward P/E at $408.22 is only ~14.9x, and TTM free cash flow of ~$1.64B on a $26.68B market cap is a ~6.1% FCF yield (flattered somewhat by float-related working capital). PEG of 2.214 looks demanding, but it is computed off trailing GAAP growth, not the ~36% Q2 adjusted-EPS growth or 20%+ revenue growth the business is currently posting. Verdict: fair-to-slightly-attractive on cash earnings, full on GAAP, with the entire debate resting on whether the GAAP-to-adjusted gap is accounting noise or real economic cost. Leverage (D/E 2.999, long-term debt $6.10B, current ratio 0.972) justifies a discount to the historical multiple.

The unusual thing here is that the market is not pricing in the bull case: at ~15x forward adjusted cash EPS, a business growing revenue 20%+ with a fresh guidance raise trades below its historical earnings multiple, which is why sell-side targets cluster $456–$536. That discount is not free money — the market is discounting the adjusted numbers, and it has grounds to. The single number that resolves this is operating margin in the Q3 2026 report (expected around Nov 4, 2026). If Q2 2026's 35.2% margin was a one-quarter artifact of acquisition/integration or divestiture-related charges tied to the portfolio rotation and it normalizes back toward 40–44%, GAAP EPS converges on the adjusted trajectory and 17–20x on roughly $31 of FY2027 adjusted EPS implies fair value of about $530–$620. If 35% is the new run rate because the mix is shifting to lower-margin revenue, adjusted estimates get cut in H2 and the 'cheap' 15x is deserved. Practically: this is a verify-with-the-next-filing stock, not a the-multiple-makes-it-safe stock — the low forward multiple is a question, not an answer.

As of 2026-09-13, RSI-14 stood at 53.66 — squarely neutral, neither overbought nor oversold. Price of $408.22 sat -0.49% below the 20-day SMA (roughly $410), +4.62% above the 50-day (roughly $390), and +20.24% above the 200-day (roughly $340): a functioning uptrend taking a breather, not a reversal. The 52-week range is $252.84–$427.46, so $408.22 is about 89% of the way up that range — extended, though not stretched on momentum. Entry-timing implication: buying here means paying near the top of a 12-month range after a +28.56% six-month run, so a staged entry with room to add on a pullback toward the 50-day (~$390) or 200-day (~$340) offers better risk/reward; a clean close above $427.46 would confirm trend continuation and mute the 'extended' objection.

• Interest rates and float income: Corpay earns yield on customer funds and card balances, so a faster-than-expected rate-cut cycle compresses a high-margin revenue stream — partially offset by cheaper interest on $6.10B of long-term debt.
• FX volatility and cross-border volume: multi-currency accounts and cross-border payments are core profit pools; a weaker dollar lifts reported revenue while unusually low FX volatility narrows spreads (and vice versa).
• Fuel prices and fleet activity: vehicle payments revenue is tied to fuel spend and miles driven, so sustained high fuel prices can dampen commercial card volumes while falling fuel prices reduce spend per transaction — both directions create quarterly top-line noise.
• Regulatory and compliance cost inflation: global AML/KYC, payments licensing, and interchange/card-fee scrutiny raise the fixed opex base — relevant directly to the Q2 2026 operating expense jump to $592M.
• Fintech/bank competition in B2B payments and payables automation: the strategic rotation toward digital B2B puts Corpay against well-capitalized specialists and bank platforms, pressuring pricing over time.

• Q3 2026 earnings, expected around Nov 4, 2026: operating margin normalization (or not) after Q2's 35.2% print, cross-border volume growth, and any change to FY2026 guidance implying ~11–13% H2 revenue growth.
• Continued analyst target revisions — Wolfe at $530 (Aug 24, 2026) and Scotiabank's Street-high $536 initiation (Aug 31, 2026) show the sell-side is willing to chase; further raises could pull the stock toward the consensus $456.50 target.
• Execution on the portfolio rotation toward scalable digital B2B and cross-border platforms, including any further acquisitions or divestitures that reshape the margin mix.
• Rate path: cuts pressure float revenue but also lower interest expense and refinancing costs on $6.10B of debt — net effect depends on timing and magnitude.
• Capital allocation cadence: ~$1.64B of TTM free cash flow funds buybacks and deleveraging, both of which can support per-share earnings independent of revenue growth.

• The GAAP-to-adjusted earnings gap: Q2 2026 adjusted cash EPS rose 36% to $7.00 while GAAP EPS fell to $3.70 from $3.98 and operating margin collapsed to 35.2% from 43.5%. If that opex gap is structural (lower-margin acquired revenue, integration costs, credit losses) rather than one-time, the entire '15x forward is cheap' argument collapses.
• Balance sheet leverage: debt-to-equity of 2.999, $6.10B of long-term debt against $3.16B of cash, and a current ratio of 0.972 leave less cushion than the headline cash flow suggests, and make the equity sensitive to rates and refinancing conditions.
• Float income dependence: a meaningful slice of high-margin revenue comes from yield on customer balances, which a rapid rate-cut cycle can compress faster than volume growth offsets.
• Working-capital-driven FCF volatility: free cash flow was -$108M in Q1 2026 and -$430M in Q3 2025 versus +$1.42B in Q2 2026 — quarterly FCF headlines are noise, and the TTM figure is flattered by float swings.
• Cyclical exposure to fleet/fuel activity and small-business credit quality; a macro slowdown would hit both transaction volumes and customer credit losses simultaneously, while the FY2026 revenue guide already implies an H2 growth slowdown to ~11–13% from ~21–25% in H1.

Corpay is a genuinely good business executing on the top line — revenue growth inflected from ~7% in early 2025 to ~21–25% in the last two quarters, gross margin is 73%+, ROE is 27.5%, and the stock trades at ~14.9x the $27.385 FY2026 adjusted cash EPS management just guided to with a ~6% TTM FCF yield. That is not an expensive setup, and it is why the sell-side targets sit $456–$536. But the honest caveat is that the quality of those adjusted earnings needs verification: Q2 2026 GAAP operating margin fell 830bp YoY and GAAP EPS declined even as adjusted EPS jumped 36%, the balance sheet carries 3x debt-to-equity, and management's own guidance implies a sharp H2 revenue growth deceleration. I would not chase at $408 near the 52-week high ahead of the Q3 print; a staged position, adding on a pullback toward the 50-day (~$390) and letting the November margin number confirm or refute the thesis, is the more defensible posture. Business quality: above average. Current risk/reward at this price: roughly balanced, not compelling.

Applied a justified 17.0x forward P/E to the FY2026 adjusted cash EPS of $27.385 given in the data (which matches the midpoint of management's raised $27.15–$27.55 guidance) — 17.0x × $27.385 = $465.5. The multiple is a deliberate discount to the stock's own 5-year average P/E of 20.17x to reflect 3x debt-to-equity leverage, float-rate sensitivity, and the unresolved GAAP-to-adjusted earnings gap, while still crediting 20%+ revenue growth and a ~6.1% TTM free cash flow yield (roughly $1.64B TTM FCF on a $26.68B market cap), which independently supports the $450–$500 area. The result sits just above the $462.18 recent average analyst target but is derived from the multiple and the earnings figure, not copied from it.